• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of viral antigen specific immunotherapy for Epstein-Barr virus related gastric cancer.

Research Project

Project/Area Number 12671249
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionKyoto Prefectural University of Medicine

Principal Investigator

UEDA Yuji  Kyoto Prefectural University of Medicine, Digestive Surgery, Assistant Professor., 医学部, 助手 (60254356)

Co-Investigator(Kenkyū-buntansha) 竹迫 一迫  宝酒造, バイオ研究所, 副所長
YAMAGISHI Hisakazu  Kyoto Prefectural University of Medicine, Digestive Surgery, Professor., 医学部, 教授 (40128723)
MATSUDA Osamu  Kyoto Prefectural University of Medicine, Digestive Surgery, Assistant Professor., 医学部, 助教授 (00271164)
TAKESAKO Kazutoh  Takara Shuzo, Biotechnology Laboratories, Chief Researcher
竹迫 一任  宝酒造, バイオ研究所, 副所長
Project Period (FY) 2000 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥1,800,000 (Direct Cost: ¥1,800,000)
Fiscal Year 2001: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 2000: ¥1,300,000 (Direct Cost: ¥1,300,000)
KeywordsEBV (Epstein-Barr Virus) / Gastric Cancer / Tumor Antigen Peptide / Tumor Specific Immunotherapy / Cancer vaccine Therapy / LMP2(Latent Membrane Protein 2)
Research Abstract

(1) Cytotoxic T cell(CTL) induction with latent membrane protein 2(LMP2) epitope peptide -loaded dendritic cells(DCs).
We synthesized the LMP2 peptide, TYGPVFMCL(HLA-A24 restricted), and established CTL line by stimulating PBMCs from HLA-A24 positive healthy donors in vitro with LMP2 peptide-loaded DCs. This CTL could lyse the target cells pulsed with this peptide, but couldn't lyse LMP2-CDNA transformed target cells.
(2) CTL induction with autologous EBV transformed B cell line(LCL).
In order to establish LCL, concentrated supernatant from B95-8 cultures, a human type1 EBV-transformed marmoset B-cell line, was added to a healthy donor's PBMCs. PBMCs from healthy donors were stimulated in vitro with autologous LCL. This LCL-induced CTL recognized the full repertoire of EBV latency antigens. We selected LMP2-specific CTL line after 5lCr release assay.
(3) Detection of EBV-DNA by polymers chain reaction (PCR).
In order to detect EBV related gastric cancers from patients underwent gastorectomy in our institute, we performed PCR and southern hybridization. After that, we tried to establish LMP2 positive cell lines of gastric cancer which could be useful targets for CTL-based immunotherapy.

Report

(3 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report
  • Research Products

    (13 results)

All Other

All Publications (13 results)

  • [Publications] 上田祐二: "「癌化学療法-最近の進歩-」消化器癌"京都府立医科大学雑誌.

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 上田祐二: "造血幹細胞移植の現状と今後の展望〜樹状細胞を用いた免疫細胞療法〜"医薬ジャーナル.

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Tsuyosi Itoh, Yuji Ueda, et al.: "Immunotherapy of Solid Cancer using Dendritic Cells Pulsed with the HLA-A24-restricted Peptide of Carcinoembrionic Antigen"Cancer Immunol Immunother. 50(in press). (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Tsuypshi Itoh, Yuii Ueda. Hisakazu Yamagishi. et al.: "lmmunotherapy of Solid Cancer using Dendritic Cells Pulsed with the HLA-A24-restricted Peptide of Carcinoembrionic Antigen"Cancer Immunol Immunother. 50(accepted (in press)). (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Yuii Ueda. Akeo Hagiwzra, Hisakazu Yamagishi: "Cancer Vacine Therapy as Tumor Dormancy Therapy againat Advanced digestive Tract Cancer"Jpn. J. Gastroenterol Surg.. 34(4). 409-414 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Yuji Ueda, Hisakazu Yamagishi: "Active Specific Immunotherapy Using CEA peptide and Dendritic Cells-Problems in Clinical Trials and Improvement in Therapeutic Methods"Biotherapy. 14(12). 1183-1189 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 上田 祐二: "「癌化学療法-最近の進歩-」消化器癌"京都府立医科大学雑誌. 110(7). 617-625 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 上田 祐二: "造血幹細胞移植の現状と今後の展望〜樹状細胞を用いた免疫細胞療法〜"医薬ジャーナル. 37(3). 179-183 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 上田祐二: "癌免疫と樹状細胞〜単球系樹状細胞のin vitro誘導と腫瘍抗原ペプタイドを用いた免疫細胞治療への応用〜"医学のあゆみ. 192(9). 879-882 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 上田祐二: "進行癌治療とワクチン療法"癌治療と宿主. 12(2). 179-186 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 上田祐二: "CEA由来ペプチドと樹状細胞を用いた特異能動免疫療法〜臨床試験をめぐる課題と治療方法の改変〜"Biotherapy. 14(12). 1183-1189 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 上田祐二: "進行消化器癌に対する癌ワクチン療法のtumor dormancy therapyとしての可能性"日本消化器外科学会雑誌. 34(4). (2001)

    • Related Report
      2000 Annual Research Report
  • [Publications] 山岸久一: "癌のワクチン療法(癌の治療戦略-現況と展望-)"外科治療. 82. 691-695 (2000)

    • Related Report
      2000 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi